North America Cephalosporin Drugs Market (2019-2025)

North America Cephalosporin Drugs Market (2019-2025)

  • July 2019 •
  • 98 pages •
  • Report ID: 5807181 •
  • Format: PDF
The North America Cephalosporin Drugs Market would witness market growth of 4.69% CAGR during the forecast period (2019–2025). Market growth is driven by the implementation of combination drugs like various antibacterials or antibacterials coupled with an inhibitor. It is anticipated that the use of combination drugs will reduce the likelihood of developing antibiotic-resistant bacterial strains, which is supposed to boost the market growth.

Compared to the first and second generations, Cephalosporin Drugss of the third generation are more efficient against Gram-negative bacteria. They are also more effective against bacteria that can be resistant to prior Cephalosporin Drugs generations. Cefepime (Maxipime) is the only Cephalosporin Drugs of the fourth generation accessible in the U.S. Although it is efficient against a multitude of Gram-positive and Gram-negative organisms, it is generally reserved for more serious diseases. The fifth-generation Cephalosporin Drugs, ceftaroline (Teflaro) may be used to treat bacteria that are resistant to penicillin antibiotics, including resistant species Staphylococcus aureus (MRSA) and Streptococcus.

Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.

Scope of the Study

Market Segmentation:

By Generation

• First-Generation Cephalosporin

• Second-Generation Cephalosporin

• Third-Generation Cephalosporin

• Fourth-Generation Cephalosporin

• Fifth-Generation Cephalosporin

By Application

• Respiratory Tract Infection

• Skin Infection

• Ear Infection

• Sexually Transmitted Infection

• Others

By Route of Administration

• Injections

• Oral Drugs

By Type

• Branded

• Generic

By Country

• US

• Canada

• Mexico

• Rest of North America

Companies Profiled

• ABBOTT Laboratories

• Teva Pharmaceuticals Industries Ltd.

• Johnson and Johnson

• GlaxoSmithKline PLC (GSK)

• Pfizer, Inc.

• Merck & Co., Inc.

• Bayer AG

• Baxter International, Inc.


• Novartis AG

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free